ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "dermatomyositis"

  • Abstract Number: 1851 • 2018 ACR/ARHP Annual Meeting

    Physical Function Trajectories in Children with Juvenile Myositis

    Kaveh Ardalan1, Elizabeth L. Gray2, Julia (Jungwha) Lee2, Madison L. Wolfe3, Gabrielle A. Morgan4 and Lauren M. Pachman5, 1Departments of Pediatrics and Medical Social Sciences, Division of Rheumatology, Northwestern University Feinberg School of Medicine/Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 2Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Creighton University School of Medicine, Omaha, NE, 4Cure JM Program of Excellence in Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 5Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL

    Background/Purpose: Juvenile myositis (JM) is an inflammatory disease that causes muscle weakness, skin rashes, and significant deconditioning. Little is known about long-term resolution of physical…
  • Abstract Number: 2163 • 2018 ACR/ARHP Annual Meeting

    Prevalence and Incidence of Idiopathic Inflammatory Myopathies in Korea:a Nationwide Population-Based Study over 10 Years

    Yoon-Kyoung Sung1, Hyoungyoung Kim2, Jisun Myung3, Eunwoo Nam3, Sun-Young Jung4, Eun Jin Jang5, Dae-Hyun Yoo6 and Soo-Kyung Cho2, 1Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), 2Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), 3Biostatistical Consulting and Research Lab, Medical Research Collaborating Center, Hanyang University, Seoul, Korea, Republic of (South), 4College of Pharmacy, Chung-Ang University, Seoul, Korea, Republic of (South), 5Information Statistics, Andong National University, Andong-si, Korea, Republic of (South), 6Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)

    Prevalence and Incidence of idiopathic Inflammatory Myopathies in Korea: a Nationwide Population-based Study over 10 yearsYoon-Kyoung Sung1, Hyoungyoung Kim1, Jisun Myung2, Eunwoo Nam2, Sun-young Jung3,…
  • Abstract Number: 2287 • 2018 ACR/ARHP Annual Meeting

    Interim Results of an Open-Label Study Assessing Efficacy and Safety of Adrenocorticotropic Hormone Gel for Treatment of Refractory Cutaneous Manifestations of Dermatomyositis

    Anthony Fernandez, Dermatology and Pathology, Cleveland Clinic, Cleveland, OH

    Background/Purpose: Cutaneous dermatomyositis (DM) is often refractory to multiple medications, suggesting better treatments are needed.  Adrenocorticotropic hormone gel is a repository corticotropin injection that is…
  • Abstract Number: 2291 • 2018 ACR/ARHP Annual Meeting

    Longitudinal Course of the Disease in Anti-Mi2 Patients: More Intense Muscle Weakness, Good Response to Treatment and Progressive Reduction of Autoantibody Titers

    Iago Pinal-Fernandez1,2, Katherine Pak3, Maria Casal-Dominguez4,5, Wilson Huang4, Jemima Albayda6, Eleni Tiniakou7, Julie J. Paik1, Christopher A. Mecoli8, Sonye K. Danoff9, Lisa Christopher-Stine9 and Andrew Mammen3,10, 1Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Muscle Diseases Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases. National Institutes of Health, Bethesda, MD, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 4NIAMS, NIH, Bethesda, MD, 5Johns Hopkins Medical School, Baltimore, MD, 6Johns Hopkins University School of Medicine, Baltimore, MD, 7Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 8Internal Medicine/Rheumatology, Johns Hopkins University, Baltimore, MD, 9Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 10Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Autoantibodies targeting the Mi-2 (Mi-2a and Mi-2b) nuclear antigen in patients with dermatomyositis (DM) were first described in 1985. However, little is known about…
  • Abstract Number: 1732 • 2017 ACR/ARHP Annual Meeting

    The Characteristic T-Cell Receptor-Mediated Signaling of Peripheral Blood T Cells in Dermatomyositis and Polymyositis

    Yasuhiro Shimojima1, Dai Kishida2 and Yoshiki Sekijima2, 1Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, 2Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan

    Background/Purpose: In dermatomyositis (DM) and polymyositis (PM), the characteristics of T cell expression in peripheral blood have been previously described; especially, decreased expression of interferon-γ…
  • Abstract Number: 2613 • 2017 ACR/ARHP Annual Meeting

    Antimalarial Drug Toxicities in Rheumatic Skin Disease Patients

    Lavanya Mittal1, Lingqiao Zhang2, Rui Feng2 and Victoria Werth1, 1Department of Dermatology, Corporal Michael J. Crescenz VAMC, Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2Department of Biostatistics and Epidemiology at the Hospital of the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Although existing evidence demonstrates the efficacy of antimalarials for rheumatic skin disease, the safety of these medications, and particularly quinacrine, remain debated. Quinacrine may…
  • Abstract Number: 1801 • 2017 ACR/ARHP Annual Meeting

    Quantifying Clinical and Economic Outcomes Associated with Chronic Corticosteroid Exposure in a US Population

    J. Bradford Rice1, Alan White1, Andrea Lopez1, Aneesha Wagh1, Yimin Qin2, Ghaith Mitri2, Laura Bartels-Peculis2, Gosia Ciepielewska2 and Winnie Nelson3, 1Analysis Group, Inc., Boston, MA, 2Mallinckrodt Pharmaceuticals, Hampton, NJ, 3Health Economics and Outcomes Research, Mallinckrodt Pharmaceuticals, Hampton, NJ

    Background/Purpose:  Corticosteroids (CS) are commonly used for rheumatologic conditions, and known to cause systemic adverse events (AEs), particularly when used at high doses for prolonged…
  • Abstract Number: 2130 • 2017 ACR/ARHP Annual Meeting

    Joint Manifestations in Patients Diagnosed with Idiopathic Inflammatory Myopathy: Multicenter Registry on Inflammatory Myositis from the Rheumatology Society in Madrid, Spain

    Larissa Valor1, Diana Hernández-Flórez2, Julia Martínez-Barrio3, Beatriz E. Joven4, Laura Nuño5, Carmen Larena6, Irene Llorente7, Carmen Barbadillo8, Paloma Garcia De La Peña9, Lucía Ruíz Gutiérrez10, Henry Moruno Cruz11, Tatiana Cobo-Ibáñez12, Raquel Almodóvar González13, Leticia Lojo14, MARIA JESUS GARCIA DE YEBENES Y PROUS15 and Francisco Javier López Longo16, 1Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 2Rheumatology, Gregorio Marañón University General Hospital, Madrid, Spain, 3Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 4Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, 5Servicio de Reumatologia, Hospital Universitario La Paz, Madrid, Spain, 6Hospital Gregorio Marañón, Madrid, Spain, 7Rheumatology, H.U. La Princesa, Madrid, Spain, 8Hospital Universitario Puerta de Hierro, Madrid, Spain, 9Rheumatology, Hospital Madrid Norte Sanchinarro, Madrid, Spain, 10Pediatric Rheumathology Unit, University Children's Hospital Niño Jesús, Madrid, Spain, 11University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcalá de Henares, Madrid, Spain, 12Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, 13Rheumatology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain, 14Rheumatology, Hospital Universitario La Paz, Spain, Spain, 15Institute for Musculoskeletal Health, Madrid, Spain, 16Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) comprise a heterogeneous group of autoimmune conditions characterized by muscle non-suppurative inflammation, progressive muscle weakness and a variety of extra-muscular…
  • Abstract Number: 2132 • 2017 ACR/ARHP Annual Meeting

    Angiogenesis and VEGF-Expressing Cells Are Identified Predominantly in the Fascia Rather Than the Muscle in the Early Phase of Dermatomyositis

    Ken Yoshida1,2, Haruyasu Ito1, Kazuhiro Furuya1, Taro Ukichi1, Kentaro Noda1 and Daitaro Kurosaka1, 1Division of Rheumatology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan, 2Internal Medicine, Jikei University School of Medicine, Tokyo, Japan

    Background/Purpose: We previously showed that fasciitis is a frequent manifestation of the disease in dermatomyositis (DM) but not in polymyositis (PM) and that DM-associated fasciitis…
  • Abstract Number: 2140 • 2017 ACR/ARHP Annual Meeting

    Infections and Medications Associated with Onset of Myositis in Myovision, a National Myositis Patient Registry

    Lisa G Rider1, Payam Noroozi Farhadi1, Nastaran Bayat1, Jesse Wilkerson2, Abdullah Faiq1, John McGrath2, Hermine I. Brunner3, Bob Goldberg4 and Frederick W Miller1, 1Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, 2Social and Scientific Systems, Inc., Durham, NC, 3Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4The Myositis Association, Alexandria, VA

    Background/Purpose: Myositis is a rare systemic autoimmune disease with suspected environmental and genetic risk factors, but little is known about specific infections and medications that…
  • Abstract Number: 2141 • 2017 ACR/ARHP Annual Meeting

    Quantitative Nailfold Video Capillaroscopy Parameters Correlate with Dermatomyositis Activity and Damage

    Hans Prakash1, Diego Song1, Daniel Lichy1, Pranay Rao2, Mina Jain3, Joseph Shrader3, Frederick W Miller4, Adam Schiffenbauer5, Alexander Gorbach1 and Lisa G Rider5, 1National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, 2National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, bethesda, MD, 3Rehabilitation Medicine Department, National Institutes of Health, Bethesda, MD, 4Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, 5Environmental Autoimmunity Grp, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD

    Background/Purpose: To assess microvascular structure and function in patients with adult dermatomyositis (DM) and juvenile dermatomyositis (JDM), we have designed and built a mobile, high-resolution…
  • Abstract Number: 2147 • 2017 ACR/ARHP Annual Meeting

    Dysphagia in Inflammatory Myositis: A Study of the Structural and Physiologic Changes Resulting in Disordered Swallowing

    Alba Azola1, Tae Chung2, Rachel Mulheren2, Genevieve Mckeon2, Lisa Christopher-Stine3 and Jeffrey Palmer2, 1Physical Medicine and Rehabilitation, Johns Hopkins University, Lutherville, MD, 2Johns Hopkins University, Baltimore, MD, 3Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: The prevalence of dysphagia in patients with inflammatory myopathies has been reported to be as high as 60% (1). Aspiration pneumonia is one of…
  • Abstract Number: 2151 • 2017 ACR/ARHP Annual Meeting

    The Predictive Risk Factors for Opportunistic Infection during Treatment for Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease

    Yumiko Sugiyama1,2, Ryusuke Yoshimi1,2, Maasa Tamura2,3, Naoki Hamada1,2, Hideto Nagai1,2, Naomi Tsuchida1,4, Yosuke Kunishita1,2, Yutaro Soejima1,2, Daiga Kishimoto1,2, Reikou Kamiyama1,2, Kaoru Minegishi1,5, Yohei Kirino1,2, Shigeru Ohno1,6 and Hideaki Nakajima2, 1Y-CURD Study Group, Yokohama, Japan, 2Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 3Y-CURD Study Group, Yokohma, Japan, 4Department of Hematology and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 5Rheumatic Disease Center, Yokohama City University Medical Center, Yokohama, Japan, 6Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan

    Background/Purpose: Although concomitant infectious diseases are the predominant causes of death in patients with polymyositis (PM)/dermatomyositis (DM)-associated interstitial lung disease (ILD), intensive immunosuppressive treatment are…
  • Abstract Number: 2158 • 2017 ACR/ARHP Annual Meeting

    HLA-DRB1*04:03/*04:06 As the Genetic Susceptibility to Dermatomyositis Positive for Anti-Transcriptional Intermediary Factor 1-γ Antibody in Japanese Population

    Yukie Yamaguchi1, Masataka Kuwana2, Miwa Kanaoka1, Tomoya Watanabe1, Naoko Okiyama3, Takahisa Gono2, Masanari Kodera4, Takeshi Kambara5, Yasuhito Hamaguchi6, Mariko Seishima7, Kazuhiko Takehara6, Manabu Fujimoto3 and Michiko Aihara1, 1Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 3Department of Dermatology, University of Tsukuba, Tsukuba, Japan, 4Department of Dermatology, Japan Community Health care Organization Chukyo Hospital, Nagoya, Japan, 5Department of Dermatology, Yokohama City University Medical Center, Yokohama, Japan, 6Department of Dermatology, Kanazawa University, Kanazawa, Japan, 7Department of Dermatology, Gifu University Graduate School of Medicine, Gifu, Japan

    Background/Purpose: Dermatomyositis (DM) is characterized by inflammation of the skin and skeletal muscle, and is occasionally complicated by interstitial lung disease or concomitant malignancy. It…
  • Abstract Number: 2159 • 2017 ACR/ARHP Annual Meeting

    Dermatomyositis Acute Onset/Flares Following Ingestion of Isalean® Herbal Supplement: Clinical and Immunostimulatory Findings

    Majid Zeidi1,2, Peter B Chansky1,2 and Victoria P Werth3,4, 1Department of Dermatology, Corporal Michael J. Crescenz VAMC, PHILADELPHIA, PA, 2Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 3University of Pennsylvania and the VA Medical Center, Philadelphia, PA, 4Department of Dermatology, Corporal Michael J. Crescenz VAMC, Philadelphia, PA

    Background/Purpose : The use of complementary and alternative medicine (CAM) has gained popularity in the United States over the last few decades. Herbal supplements have…
  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19
  • 20
  • 21
  • …
  • 24
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology